A recent deal between Neumirna Therapeutics and ten23 health seeks to speed up the clinical translation of NMT.001, a microRNA-targeting RNA therapy for drug-resistant epilepsy.

Key Takeaways

  • The partnership between Neumirna Therapeutics and ten23 health aims to accelerate the clinical development of NMT.001, a microRNA-targeting RNA therapy for drug-resistant epilepsy.
  • By combining ten23 health’s formulation and manufacturing expertise with Neumirna’s RNA innovation, the collaboration seeks to bring NMT.001 into clinical trials efficiently.
  • This alliance reflects the growing momentum and investment in RNA and oligonucleotide-based therapies.

Combining Expertise for Clinical Progress

ten23 health is a human-centric CDMO partner that is highly respected by industry partners and biotech startups. The primary objective is to bring the NMT.001 candidate into clinical trials by combining ten23’s formulation and manufacturing expertise with Neumirna’s RNA innovation.

Leadership Perspectives

Dr Susanne Jorg, COO of ten23 health, stated: “We are honoured to collaborate with Neumirna Therapeutics and support their mission to address critical medical needs through innovative healthcare solutions.”

She continued, “Our expertise and ongoing research in drug product development, manufacturing, and testing of oligonucleotide therapies, including RNA, align seamlessly with Neumirna's commitment to delivering life-changing therapies. We share a common goal of improving patient care and look forward to advancing this program effectively and efficiently.”

Shared Vision for Patient Impact

This sentiment was shared by Dr. Ellen Donnelly, CEO at Neumirna Therapeutics, who expressed that ten23 health’s expertise will help strengthen Neumirna Therapeutics’ ability to accelerate the development of their pipeline.

Growing Momentum in RNA Therapies

This partnership has occurred at a time of growing interest and momentum for RNA and oligonucleotide-based therapies. In areas with high unmet medical needs like chronic neurological diseases, there has been increasing investment in RNA and oligonucleotide-based therapies.